Fri, Dec 26, 2014, 7:05 AM EST - U.S. Markets open in 2 hrs 25 mins

Recent

% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • jim.beemer@rocketmail.com jim.beemer Oct 14, 2013 8:59 AM Flag

    Complete Enrollment

    In the next month or two NeoStem should announce complete enrollment. Then, we are just six months away from Phase 2 data. This will be a point where the market will assess the product's strong data to date, and more AMR-001/Baxter comparisons will be made. Expect a predata run-up, and if data is good, expect Baxter to #$%$ up NeoStem fast.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Much sooner than the "year and a half" untill phase 2 data that some bashers on this board would have us believe.

      Sentiment: Strong Buy

    • Baxter's own phase 3 CD34+ trial was announced 28 Feb 12. From their press release.

      "The trial will enroll approximately 450 patients across 50 clinical sites in the United States, who will be randomized to one of three arms: treatment with their own autologous CD34+ stem cells, treatment with placebo (control), or unblinded standard of care. The primary objective is to evaluate the efficacy of treatment with CD34+ stem cells to improve the functional capacity of patients with CMI, as measured by a change in total exercise capacity at 12 months following treatment. Secondary objectives include reduced frequency of angina episodes at 12 months after treatment and the safety of targeted delivery of the cells."

      Baxter's treatment and goals differ from NeoStem's current phase 2 trial, but one would think NBS would benefit from positive Baxter results. Assuming Baxter completed enrollment during 2012, results should be released early 2014.

      Sentiment: Strong Buy

 
NBS
3.27+0.02(+0.62%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Avis Budget Group, Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 12:59 PM EST